Feeds:
Posts
Comments

Posts Tagged ‘hormone-refractory prostate cancer’

NORWAY POST: Alpharadin, a new drug that treats men with hormone-refractory prostate cancer that has spread to the bone, will be developed by a Norwegian cancer therapeutics company and global drugs giant Bayer. READ MORE>

Read Full Post »

JUNE 11: NEW PROSTATE CANCER INFO-LINK: It is well understood that skeletal complications are a crucial factor in the quality of life and the prognosis of patients with hormone-refractory prostate cancer; however, their true prevalence and impact on the prognosis remain largely unknown. READ MORE>

Read Full Post »